Aevi Genomic Medicine Inc (GNMX)

Currency in USD
0.1659
0.0000(0.00%)
Closed·
Showing Aevi Genomic Medicine historical data. For real-time data please try another search
Day's Range
0.15300.1836
52 wk Range
0.00000.1836
Key Statistics
Prev. Close
0.185
Open
0.1836
Day's Range
0.153-0.1836
52 wk Range
0-0
Volume
-
Average Volume (3m)
294.97K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Aevi Genomic Medicine Inc Company Profile

As of February 3, 2020, Aevi Genomic Medicine, LLC was acquired by Cerecor Inc. Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidate is AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn’s disease. The company also develops AEVI-005, a monoclonal antibody, which is in preclinical research program for the treatment of auto-immune pediatric disease. In addition, it focuses on evaluating the anti-seizure activity of AEVI-004 in a preclinical model as part of the National Institutes of Health Epilepsy Treatment Screening Program. It has a development and option agreement with Kyowa Hakko Kirin Co., Ltd. related to AEVI-002 and AEVI-005. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Earnings

Latest Release
Oct 29, 2020
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GNMX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.